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Sickle cell disease (SCD) is described as the first identi-fied “molecular” disease since its manifestations stem from a substitution of valine for glutamic acid in the 
structure of the β chain hemoglobin molecule.1 As a result 
of this change, RBCs form characteristic “sickle” shapes and 
the surface of these RBCs attract each other, polymerizing 
when in a low oxygen environment. This seemingly “small” 
variation in the structure of the RBC causing polymerization 
leads to manifestations such as chronic occlusion of blood 
vessels (vaso-occlusion), reduced blood flow to vital organs 
(ischemia), and alterations of the immune system. In ad-
dition, the abnormal sickle cells are prematurely removed 
from circulation, resulting in hemolytic anemia. Transfu-
sion is a vital component of the treatment of some of the 
complications of SCD. It is also a modality used to prevent 
some of these complications from occurring. Patients with 
SCD are unique because those who are transfused usually 
require chronic transfusion, resulting in exposure to many 
different blood donors over the course of treatment. In 
addition, most patients with SCD in the United States are 
African American, and most donors are Caucasian from 
Western European descent. As a result of this difference, 
patients with SCD are exposed to RBC antigens that they 
lack, putting them at risk for forming alloantibodies, de-
fined as RBC alloimmunization.2 Therefore, it is important 
to understand the issues involved in the safe and effective 
transfusion of patients with SCD.
Defining Hemoglobinopathies
 Hemoglobin (Hgb) is made up of iron (heme) and 4 
globin chains. The type of globin chains determines the type 
of hemoglobin (see Table 1).3
 Since SCD is characterized by the presence of an abnor-
mal or variant hemoglobin, hemoglobin S, it is characterized 
as a hemoglobinopathy. The composition of hemoglobin for 
patients with homozygous SS is presented in Table 2.
 There are a variety of other abnormal hemoglobins that 
may be present with or without Hgb S. The type of hemo-
globin a person has is based on patterns of inheritance. If 
each parent contributes hemoglobin S, the child can inherit 
two copies and is designated as Hgb SS, or is homozygous 
for hemoglobin S. If a child only inherits one copy from one 
parent and a copy of normal hemoglobin, Hgb A, they are 
designated as Hgb AS, or heterozygous. These individuals 
are usually asymptomatic, and only develop manifestations 
under rare circumstances, where they become hypoxic, 
such as at high altitudes. Therefore, not every person with 
an abnormal hemoglobin develops or exhibits signs and 
symptoms. Although Hgb S is found worldwide, it is most 
commonly found in western Africa. About one in every 400–
500 African Americans, or 80,000, has SCD. About 9000 
African Americans, or one in 12, have sickle cell trait.4
 On the other hand, patients who have manifestations 
of their sickle hemoglobin are considered to have SCD. This 
includes patients who are homozygous for Hgb SS, as de-
scribed previously. In addition, some patients who inherit 
Hgb S from one parent and another abnormal hemoglobin 
from the other parent can also have SCD. Common exam-
ples are designated as Hgb SC and Sβ-thalassemia. These 
individuals can have a milder clinical course than that of 
individuals who are homozygous for Hgb S.
 Since RBCs with Hgb S are abnormal, they are removed 
from circulation in the spleen more rapidly than normal 
RBCs. This leads to a reduced life in the circulation of 16–
20 days in comparison to 120 days for normal RBCs.5 The 
premature destruction of RBCs, with the accompanying 
decrease in hemoglobin, is classified as a hemolytic anemia.
 
Typical Laboratory Findings in Sickle Cell Disease
 Patients with SCD are commonly diagnosed after new-
born screening. In the past, young children presented with 
painful swellings of the feet and hands, a consequence of 
vaso-occlusion (see discussion on Clinical Manifestations 
of Disease).
 Many patients with SCD have anemia, with hemoglobin 
levels between 6 and 8 g/dL. Characteristic sickle shaped 
cells are seen on peripheral smear (Fig. 1). Patients do not 
always have symptomatic anemia because the body com-
pensates for the peripheral RBC destruction by increasing 
the rate of RBC production (erythropoiesis) in the bone mar-
row. Consequently, the bone marrow contains an increase 
in the number of RBC precursors. As a result, immature 
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Table 1. Composition of normal adult hemoglobin
Hemoglobin Composition Percent (%)
Hgb A α2β2 96–98
Hgb A2 α2δ2 1.5–3.5
Hgb F α2γ2 <1






*Reprinted with permission of the College of American Pathologists.
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precursors, suggestive of reticulocytes, are released from 
the marrow prematurely. Therefore, the peripheral smear 
will also show these immature RBCs, which are larger than 
mature RBCs and have a slightly blue color since they are 
not fully hemoglobinized.3 The term reticulocytes will be 
used in this education activity, and refers to these RBCs.
 Another consequence of the high rate of hemolysis and 
erythropoiesis, or increased RBC turnover, is the accumula-
tion of unconjugated or indirect bilirubin. As a result, some 
patients will have yellowing of the white of the eyes, scleral 
icterus, and skin, or jaundice. The increase in bilirubin also 
puts patients at increased risk for gallstones, and the pa-
tient may have to have their gallbladder removed. Table 3 
lists the common laboratory findings in SCD and their 
etiologies.
 Early diagnosis is essential in order to treat and even 
prevent some of the complications of SCD. In the past, 
approximately 25% of children between the ages of four 
months and five years with SCD died of pneumonia. The 
use of prophylactic penicillin in children with SCD in the 
setting of comprehensive care reduced the risk of death in 
childhood to less than 3%.6–8 Therefore, in order to be able 
to refer these patients to specialists and provide state-of-
the-art patient care, identification of children with SCD at 
birth is an important public health intervention. Screening 
can be done in the neonatal period using fetal DNA during 
pregnancy, or more commonly, performing DNA analysis 
soon after birth. Prenatal testing can be done between 14–
16 weeks of gestation in pregnancies where there is a chance 
that the baby will inherit Hgb S from both parents.1,3,4
 More commonly, newborn infants are screened through 
mandatory programs required by most states, soon after 
birth.1,3,4 Several methods exist for detecting abnormal he-
moglobins. These include:
High performance liquid chromatography (HPLC)—• 
Considered one of the best methods to be able to detect 
abnormal hemoglobins and to be able to differentiate 
them from normal hemoglobin. HPLC uses reactions in 
columns of reagents. This technique also measures the 
quantity of the various hemoglobins.
Hemoglobin electrophoresis—Separates different he-• 
moglobins according to their characteristic migration 
across a gel of either cellulose acetate at an alkaline 
pH or citrate agar at an acid pH, based on charge. The 
different types of hemoglobin will migrate at different 
rates, occupying a characteristic position on the gel.
Isoelectric focusing—If further separation is necessary, • 
then isoelectric focusing can be performed. An electric 
current is passed through the gel that has areas of dif-
ferent pH. The identity of the hemoglobin can be made 
by its pattern of migration.
Solubility test—Taking advantage of the fact that re-• 
duced Hgb S is insoluble in certain solutions, a simple 
solubility test can be used to detect the presence of Hgb 
S. After lysis, RBCs are reduced by sodium hydrosulfite. 
If Hgb S is present, the solution will be turbid; if not 
present, then the hemoglobin remains in solution and 
the suspension is clear. Since this test requires a certain 
amount of whole blood, it is not routinely used for new-
born screening. Note that this test will just detect the 
presence of Hgb S, so patients who have sickle cell trait 
(heterozygous for Hgb S) will also be positive.
When performing patient testing, it is always important to 
follow the package insert and ensure that proficiency test-
ing is performed in compliance with the Clinical Laboratory 
Improvement Amendments of 1988 (CLIA). CLIA regula-
tions require that laboratories enroll in a Centers for Medi-
care and Medicaid Services (CMS) approved proficiency 
testing (PT) program for all regulated tests that the labora-
tory performs.
Clinical Manifestations of Sickle Cell Disease
 The function of a normal RBC is dependent upon its 
ability to flow freely through blood vessels and to be flexible 
enough to move in and out of vessels and tissue where oxygen 
delivery occurs. Due to the rigidity of the sickle RBC, these 
properties are lost. Interestingly, when a patient with SCD 
has a higher percentage of hemoglobin F, the course of their 
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Table 3. Common laboratory findings in sickle cell disease
Laboratory value Etiology
Low hemoglobin and hematocrit Hemolysis
High mean cellular volume (MCV) Reticulocytes 
High white blood cell (WBC) 
count
Inflammation and increased marrow 
production
High platelet count Increased marrow production




High total and indirect bilirubin Hemolysis
High alkaline phosphatase until 
puberty
Elevated bone marrow activity
Fig. 1 The arrowed cell is a classic example of a sickle cell. Anoth-
er sickle cell is located in the upper left corner. There is a nucleated 
red blood cell in the lower right corner. The large cell in the center 
is a polychromatophilic red cell or reticulocyte. (Source: Figure 
HE-42. In: Glassy EF, ed. Color Atlas of Hematology. Northfield, IL: 
College of American Pathologists, 1998:97.)
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disease is milder and their life expectancy is longer. This is 
probably the result of the lower percentage of Hgb S in these 
patients, and that RBCs with Hgb F do not form polymers.9 
These chronic physiologic changes can lead to problems in 
all organ systems; heart, lungs, and kidneys. SCD can be 
seen as a disease based on vaso-occlusion (VOC), chronic 
hemolytic anemia, and immunologic impairment.
Occlusive Disease
 There are a variety of ways by which sickle cells cause 
obstruction. One minor mechanism is whereby irreversibly 
sickled cells obstruct small capillaries. More commonly, 
sickle cells are trapped in small venules and capillaries.1,10 
The process of sickling and occlusion involves a complex in-
teraction between chemical mediators, as well as elements 
other than the RBC itself. There is increasing understanding 
that the walls of blood vessels are involved. There appears to 
be increased adherence of sickle cells to the vascular walls, 
due to properties of the RBCs, as well as changes in the en-
dothelial cells of blood vessels. The lipid bilayer of RBCs is 
disrupted in sickle cells, causing their early removal from 
circulation. Additionally, changes in their interactions with 
other cells within the blood stream, such as sticky white 
blood cells (WBCs) and activated platelets, contribute to 
vaso-occlusion.10,11 These changes can also cause the acti-
vation of coagulation, leading to an increased risk of deep 
venous thrombosis.10,12
 Vaso-occlusion manifests itself as one of the most com-
mon findings in a patient with SCD, pain crisis. Prior to 
routine screening of newborns, children were commonly 
diagnosed with SCD prior to the age of two, with occlu-
sion in the hands and feet presenting as painful swelling, 
or dactylitis.4,5 This would not occur until six months of age 
because the higher level of fetal hemoglobin prior to six 
months is protective. Most patients will often have severe 
pain due to occlusion of blood flow to bones, bone marrow, 
muscles, or organs, and in their arms, legs, back, abdomen, 
and chest. Treatment consists of analgesia (many patients 
with SCD require chronic medication) and hydration, since 
dehydrated RBCs are more likely to sickle. The cause of cri-
sis can vary between patients and between episodes in the 
same patient, but may be related to infection, extremes of 
temperature, medication, or any other physiologic changes. 
Occlusion is also associated with bony infarcts leading to 
osteonecrosis, skin ulcers, organ occlusion (including the 
spleen, resulting in functional asplenia or autosplenecto-
my), acute chest syndrome, and cerebrovascular accidents 
or strokes.
Stroke
 Stroke in any patient is a devastating event, with ap-
proximately 11 percent of patients with Hgb SS having a 
stroke by the age of 20.13 As blood vessels become occluded, 
their diameter gets smaller and the rate of blood flow in-
creases, thereby increasing the risk of stroke. Using a type 
of ultrasound, transcranial Doppler (TCD), to measure 
blood flow through the internal carotid and middle cerebral 
arteries of the brain, a study found that one could predict 
patients at risk for a first stroke.14 Chronic transfusion ther-
apy has been used successfully to prevent primary stroke 
and then subsequent stroke (see Treatment of Sickle Cell 
Disease).15,16
Acute Chest Syndrome
 Acute chest syndrome (ACS) is the leading cause of 
death in adults with SCD and a major cause of morbidity 
in patients of all ages. It is characterized by the onset of 
worsening respiratory status, fever, and new infiltrate on 
chest x-ray. The inciting event can be respiratory infection; 
however, since a majority of cases of acute chest syndrome 
in adults follow pain crisis, it is believed that an embolus 
of fatty tissue from the bone marrow (the site of the initial 
vaso-occlusion) into the lungs is the culprit. Patients need 
enhanced oxygenation, so supplemental oxygen is admin-
istered. Transfusion is an essential component in the treat-
ment of acute chest syndrome, as will be discussed in more 
detail later.17
 Of interest, there are many investigators looking at the 
role of inflammatory chemicals in the pathophysiology of 
SCD, as well as their potential for developing new treat-
ments. For example, there is a reduction in levels of an ad-
hesion molecule (VCAM-1) in patients with SCD on chronic 
transfusion protocols.18 Therefore, chronic transfusion pro-
tocols might prevent vaso-occlusion. Another recent study 
found that the increases in the inflammatory mediator, 
secretory phospholipase A
2
, can predict acute chest syn-
drome. Transfusing when levels are elevated can prevent 
acute chest syndrome.19
Hemolytic Anemia
 The abnormal shape and surface of sickle cells result 
in their shortened life span in the circulation and lead to 
the characteristic anemia. As RBCs are cycled through the 
spleen, the site of their ultimate destruction, they also injure 
the tissue of the spleen. Their rigidity impairs their ability to 
flow smoothly through the sinusoids, and their sharp edges 
cause them to be stuck, and to damage splenic tissue. In 
children under the age of five, blood can pool in the spleen, 
which becomes a site of sequestration of RBCs. When this 
occurs, the child has a painful, enlarged spleen accompa-
nied by a drop in hemoglobin. Splenic sequestration can be 
life-threatening since there is also a drop in blood volume in 
the vasculature, or hypovolemia. Transfusion management 
is essential in these cases. Many of these patients eventu-
ally need to have their spleen removed. As a patient gets 
older, the damage to the spleen is chronic, and the spleen 
actually becomes smaller, eventually shriveling and losing 
function.1,4,5
 In order to keep up with this chronic destruction, the 
body attempts to compensate by increasing RBC produc-
tion. This chronic hemolysis may also create an inflamma-
tory state.1,10,11 Also, the free hemoglobin that is released 
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from hemolyzed RBCs causes additional damage to the lin-
ing of blood vessels.10,13 The marrow is very active, as evi-
denced by immature RBCs or reticulocytes in the peripheral 
blood. As the marrow increases production of RBCs, plate-
let and WBC production also increases. As a consequence of 
increased erythropoiesis, many patients do not suffer from 
signs and symptoms of anemia, even though they may have 
a low hemoglobin. As long as the individual can continue 
to compensate, the anemia does not present a problem. 
When the marrow cannot keep up with production (i.e., a 
lack of folic acid), or has its production impaired by viral ill-
ness, such as parvovirus B-19, an aplastic crisis may occur. 
Parvovirus B-19 is a common childhood virus responsible 
for Fifth’s Disease. This disease causes a rash, the classic 
“slapped-cheek” appearance, and high fevers. Parvovirus 
can suppress bone marrow production by destroying the 
RBC precursor cells in the bone marrow. In these cases of 
severe anemia, transfusion therapy is necessary.5
Immunologic and Infectious Manifestations
 The spleen can be affected in SCD due to occlusive forc-
es, but it is also damaged by the pointed, inflexible sickle 
cells that travel through it and are stuck. The spleen is an 
important immunologic organ, helping to fight infections 
with encapsulated organisms (S. pneumoniae, H. influ-
enzae, and N. meningitidis). Therefore, it is important to 
recognize children with SCD and immunize them. As stated 
earlier, the use of prophylactic penicillin has been found to 
reduce death in children.9,20 All infections should be treated 
aggressively.
Treatment of Sickle Cell Disease
 Prevention of early complications, such as infection, is 
important in the overall treatment plan for patients with 
SCD. As more is being learned about the basic mechanisms 
of the disease, new treatments are being developed. Anal-
gesics, including opioids, are a mainstay of treatment for 
people suffering with pain crisis. In addition, it is impor-
tant to give patients with SCD vitamins, such as folic acid, 
which are essential to the production of RBCs. Hydration is 
also key, since RBCs sickle when dehydrated. In addition, 
hydration improves the viscosity of the patient’s blood and 
allows the RBCs to move more easily. As hemoglobin rises, 
the viscosity of the bloodstream increases and there is an 
increased risk of occlusive disorders, as well as an increased 
risk of pain crisis.21 There is no data to show that transfu-
sion should be part of the routine treatment for crisis.5,20 
The role of nitric oxide is also being investigated as a thera-
peutic modality, since nitric oxide plays an important role 
in the physiology of RBCs.1,4
 Patients of all ages who have higher concentrations 
of Hgb F have milder disease and lower mortality than 
patients with lower levels of Hgb F. Increasing the pro-
duction of Hgb F seems like a reasonable therapeutic in-
tervention. In the laboratory, Hgb F has been shown to 
interfere with the polymerization of deoxygenated Hgb S. 
The chemotherapeutic agent, hydroxyurea (HU), increases 
the amount of Hgb F that is made by the bone marrow. 
RBCs with Hgb F lack the β chain, which is responsible for 
the sickling seen in Hgb S RBCs. Therefore, these RBCs 
do not sickle, nor can they polymerize. This is one of the 
mechanisms considered to be responsible for the improved 
outcomes. In addition, HU has been found to reduce WBC 
production, thereby reducing the number of circulating in-
flammatory cells, capable of adhering to blood vessel walls. 
Platelet counts also drop and this may inhibit one of the 
factors responsible for vaso-occlusion. HU also influences 
nitric oxide metabolism. Nitric oxide leads to the dilation 
of blood vessels and seems to reduce the adhesion between 
RBCs and blood vessel walls.22
 HU has been found to reduce mortality due to an induc-
tion of Hgb F and a reduction in vaso-occlusive events. In 
addition, it reduces the incidence of acute chest syndrome, 
transfusion requirements, episodes of hospitalization, 
pain crisis, and reduces blood flow through intracranial 
blood vessels, as measured by transcranial Doppler in chil-
dren.22–24 Currently, there is controversy about whether or 
not HU can be used to prevent repeat strokes as effectively 
as chronic transfusion in children.13,24,25 Since HU is a che-
motherapeutic agent, there is concern that it will have long 
term side effects. It is not used in women who are preg-
nant or planning to become pregnant. In addition, some 
patients have to discontinue therapy because their WBC 
count becomes too low. The effects of hydroxyurea are not 
immediate, generally taking a few months to be effective.23 
Therefore, it does not provide rapid response during acute 
illness.
 Bone marrow transplant, peripheral blood stem cell 
transplant, and umbilical cord blood transplant are all 
strategies that can cure SCD. Due to the morbidity and 
mortality secondary to transplant, it is important to care-
fully choose patients with severe disease with a high risk 
of morbidity and mortality, such as those with recurrent 
strokes. Therefore, trials have centered on treating children 
or young adults, and there are some encouraging results. 
Unfortunately, one impediment is the low availability of 
matched sibling donors.26–28
Transfusion Management
 Transfusion therapy should only be initiated in patients 
with signs and symptoms of anemia. As mentioned, most 
patients with SCD, though anemic, do not generally have 
daily signs and symptoms of anemia. Therefore, RBC trans-
fusion should only be used for specific indications. RBC 
transfusion, when necessary in patients with SCD, provides 
some additional benefits. While increasing the patient’s he-
moglobin, transfusion dilutes the Hgb S with Hgb A. The 
RBCs with Hgb A have longer survival than the RBCs with 
Hgb S and neither sickle nor polymerize. In addition, trans-
fusion will suppress the patient’s own erythropoiesis, or 
RBC production. As a consequence, they will produce less 
of their own Hgb S RBCs.4,5,29
S.D. Roseff
IMMUNOHEMATOLOGY, Volume 25, Number 2, 2009 71
A review of topics in SCD
 The decision to transfuse should take into account the 
known benefits in the face of risks. All blood products are 
capable of transmitting certain infectious diseases and 
causing transfusion reactions. In addition, the recipient is 
exposed to certain inflammatory mediators that accumu-
late in transfused blood and to foreign antigens from the 
donor. Exposure to foreign RBC antigens has important im-
plications for patients with sickle cell disease.
 RBCs can be transfused as a simple transfusion or via 
exchange transfusion (erythrocytopheresis).5,29 During 
simple transfusion, one or two units of RBCs are transfused 
through a peripheral IV. Exchange transfusion is usually 
performed using an automated machine that is designed to 
remove whole blood from the patient, separate into its vari-
ous components, and then discard the patient’s Hgb S RBCs. 
RBCs from the blood bank are then used as replacement. 
Typically, an RBC exchange exchanges one to two RBC vol-
umes (total blood volume × hematocrit = 1 blood volume). 
A larger bore, stiff-walled central venous catheter is usually 
required due to the flow requirements of the automated in-
strument. In the absence of automated equipment, manual 
exchange transfusion can be done. This is not optimal, since 
this can create blood pressure and volume changes during 
the alternating removal of whole blood through a peripheral 
vein with subsequent reinfusion of banked RBCs. Each type 
of transfusion has its own risks and benefits, as outlined in 
Table 4 and in Table 5.
Indications for Transfusion in Sickle Cell Disease
 Indications for transfusion in SCD include:
Aplastic Crisis: When RBC production in the bone marrow 
is interrupted, the delicate balance to maintain RBC pro-
duction during chronic hemolysis is disrupted. Therefore, 
if the patient has a drop in their hemoglobin and becomes 
symptomatic, transfusion is required until the underlying 
process abates.5,29
 Splenic Sequestration: When a child’s hemoglobin 
drops and they become symptomatic, transfusion is neces-
sary, in this setting. Of interest, transfusion increases the 
hemoglobin beyond what’s expected, so it is important to 
transfuse slowly to avoid over-transfusion. Hepatic seques-
tration can also occur.5,29
Pregnancy: In uncomplicated pregnancies, there is no im-
provement in outcomes in women who are transfused. Pa-
tients with other complications of SCD should be transfused 
accordingly.5,29,30
 Priapism: Priapism is the painful engorgement of the 
penis, as a result of vaso-occlusion. Supportive therapy 
consisting of hydration and analgesia is recommended, and 
a urologist should be consulted. When priapism does not 
resolve, simple transfusion or exchange transfusion should 
be considered. There are no studies to direct transfusion 
therapy. In addition, exchange transfusion has been associ-
ated with adverse neurologic sequelae, such as seizures and 
increases in intracranial pressure, so there is a reluctance 
to perform exchange until the patient is refractory to other 
treatments.5,29,31
 Presurgical Prophylaxis: Patients with SCD are at high 
risk for complications when undergoing major surgery. 
Currently, some practitioners recommend that patients 
be transfused to a hemoglobin of 10 g/dL prior to surgery. 
A study done comparing exchange transfusion to simple 
transfusion found that exchange transfusion is unneces-
sary.5,29,32 There are investigations underway to determine 
whether or not a hemoglobin lower than 10 g/dL is safe for 
certain surgeries.33
 Acute Chest Syndrome (ACS): Transfusion, either sim-
ple or exchange, implemented early in the course, improves 
oxygenation and alleviates organ dysfunction. For patients 
who are stable, simple transfusion should be performed. If 
the patient deteriorates, does not improve, or has a rapidly 
evolving course, exchange transfusion is recommended.17,34 
Simple transfusion should only be performed until the he-
moglobin reaches about 10 g/dL. Beyond that, there is con-
cern for vaso-occulsion.5,29
 Stroke: Due to the ease of simple transfusion in pediat-
ric patients, they usually undergo simple transfusion. For 
patients who have an initial stroke, exchange transfusion 
is used to rapidly reduce the amount of Hgb S that can be 
recruited and extend the immediate damage to the brain. 
Once a patient has a stroke, they are at risk for additional 
strokes. By performing a monthly transfusion, either sim-
ple or exchange, this risk of recurrence is reduced. A recent 
study showed that stopping monthly transfusion after the 
return of normal flow by transcranial Doppler results in 
recurrent strokes and the return of abnormal TCDs.13,15,16,35 
Of interest, during studies to reduce the risk of first stroke, 
patients on a chronic transfusion protocol also had a reduc-
tion in the risk of acute chest syndrome and a reduction in 
the number of pain crises.15,16
Table 4. The benefits and risks of simple transfusion 
Benefits Risks
Technical ease—requires only peripheral 
IV access 
Low donor exposure—only 1 or 2 units 
of RBCs necessary 
Dilution of Hgb S
Increases viscosity
Risk of iron overload
Table 5. The benefits and risks of exchange transfusion
Benefits Risks
Produces rapid reduction in Hgb S
No increase in viscosity
No risk of iron overload—some 
observe reductions in serum 
ferritin over time
Requires large gauge IV, usually 
central venous catheter
Requires expertise and special 
equipment—may require transfer of 
patient to another facility
Higher donor exposure—at least 4 
units of RBCs for an adult, usually 
more
Higher expense
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Adverse Consequences of Transfusion of Patients with 
Sickle Cell Disease
 Adverse consequences of transfusion of patients with 
SCD include:
 Alloimmunization: Due to the disparity between do-
nors and patients with SCD in the United States, patients 
with SCD are among those most frequently alloimmmu-
nized. Studies have shown that the most common antibod-
ies formed in this population are C, E, and K1.2,36 There are 
also other antibodies that are formed due to donor–recipi-
ent disparity. Therefore, in order to prevent alloimmuniza-
tion, some centers routinely perform RBC phenotypes on 
patients with SCD and only transfuse RBCs that lack C, E, 
and K1, if the patient is negative for the antigen. This strat-
egy reduces the rate of antibody formation in these at-risk 
patients.36 Despite these findings, practice is variable. 
Analyzing the results of the 2003 J-C College of American 
Pathologists Proficiency Testing Survey, Osby and Shul-
man found that only 37 percent of North American hospi-
tals routinely perform antigen typing on the RBCs of non-
alloimmunized patients with SCD. In the 439 laboratories 
that do perform RBC phenotyping, C, E, and K1 were the 
most frequent antigens that were matched.37 In a survey of 
50 academic medical centers in the US and Canada, 73 per-
cent of centers reported that they performed routine phe-
notyping with 89% of those centers also matching for C, E, 
and K1.38 There is controversy about providing RBCs that 
lack additional antigens. As you match for additional anti-
gens, it becomes more difficult to find compatible units. It is 
argued that it is a better use of resources to save those rare 
units for patients with existing antibodies.39 Another strat-
egy has been to use RBCs from donors who are ethnically 
similar to the patient, thereby creating a better chance that 
the donor and patient will match more closely.40 Whenever 
a patient develops an antibody, they will also receive RBCs 
lacking the corresponding antigen.41
 Hyperhemolytic Syndrome: A serious type of hemo-
lytic transfusion reaction, called the “hyperhemolytic syn-
drome,” can occur in the setting of transfusion. During these 
episodes, the patients are typically being transfused, and 
instead of rising, their hemoglobin falls with subsequent 
transfusion. It is felt that there is a “bystander” hemolysis of 
the patient’s own RBCs, as well as destruction of transfused 
RBCs. Of interest, the units transfused are crossmatch com-
patible, and no new alloantibodies are identified at the time 
of transfusion. Further transfusion compounds the prob-
lem. Therefore, it is important to recognize the syndrome 
and, if possible, stop transfusing. If transfusion is neces-
sary, intravenous immunoglobulin (IVIG) and intravenous 
steroids have been found to be effective. If transfusion is 
required because of life-threatening anemia, it should be 
done cautiously, using IVIG and steroids concurrently.42–44
 Iron Overload: Each unit of transfused RBCs contains 
about 200–250 mg of iron. With chronic transfusion, this 
iron accumulates and can be deposited into organs such 
as the heart, liver, and endocrine glands. In order to pre-
vent this, medications are used to remove, or chelate, iron. 
Intravenous chelators have been used, but their efficacy 
is hindered by its half-life and poor patient compliance. 
A new generation of oral chelators is effective since there 
is increased compliance, and mode of actions results in a 
more continuous chelation. Serum ferritin is monitored in 
patients on chronic transfusion protocols who have SCD.45 
The aim of treatment is to reduce serum ferritin and to 
remove iron from organs.
Transfusion Recommendations
 When a patient develops complications from SCD, it 
also makes sense not to transfuse them with RBCs with ad-
ditional Hgb S. Therefore, many laboratories will do a sim-
ple solubility test, as described earlier, and select units that 
lack Hgb S. Realize that individuals with SCD are anemic 
and cannot serve as blood donors, however, there are active 
donors with sickle cell trait.41
 Leukoreduction (LR) of blood products has been prov-
en to reduce the risk of cytomegalovirus (CMV) transmis-
sion, reduce the risk of febrile non-hemolytic transfusion 
reactions, and reduce the risk of human leukocyte antigen 
(HLA) alloimmunization.41 There are also studies, though 
controversial, that show there are deleterious immunologic 
sequelae of transfusion that are prevented by reducing the 
load of WBCs in transfused blood products. Since patients 
with SCD are chronically transfused, many believe that these 
patients should receive LR blood products. Of note, there is 
also a study that shows reduced rates of RBC alloimmuniza-
tion in patients who receive LR blood products.46 Transfu-
sion recommendations for patients with SCD are:
Blood products that are sickle hemoglobin negative• 
Blood products that are leukoreduced• 
Blood products that are negative for C, E, and K1 anti-• 
gens if the patient lacks these antigens
Blood products that are negative for any additional an-• 
tigens against which the patient has antibody
Blood products that are from African American donors, • 
if a program exists
Summary
 The substitution of one amino acid in the hemoglobin 
molecule results in sickle hemoglobin. As a result, RBCs 
sickle in low oxygen states causing occlusion of blood ves-
sels, increased viscosity, and inflammation. These RBCs 
are prematurely removed from the circulation, resulting in 
a chronic hemolytic anemia. With newborn screening and 
early treatment, the death rate among children with SCD 
has declined. In addition, a variety of treatments are being 
introduced to help manage the various manifestations of 
disease. Transfusion, simple or exchange, is a mainstay of 
therapy, since it reduces the amount of Hgb S in circulation 
and suppresses erythropoiesis. Transfusion is indicated 
for symptomatic anemia and specifically to prevent stroke 
(first or recurrent), during acute stroke, and for acute chest 
syndrome. Unfortunately, transfusion carries risks for in-
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fectious disease transmission, as well as immunologic and 
inflammatory sequelae. For patients with SCD who may be 
chronically transfused, iron overload occurs frequently. In 
addition, due to differences in RBC antigens between do-
nors and recipients, these patients are at increased risk for 
development of RBC alloantibodies, which can complicate 
further transfusion. It is, therefore, important to prevent 
alloimmunization by transfusing leukoreduced RBCs that 
match the patient for the C, E, and K1 antigens. Human 
progenitor cell (from bone marrow, peripheral blood stem 
cells, or umbilical blood) transplant can cure the disease, 
and is used for patients with severe disease for whom con-
ventional therapy may not be effective.
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